Cipla is aiming to build a strong presence in Kenya. In line with its global strategy, Cipla continues to retain ownership of its marketing authorisations and trademarks for its products in Kenya and will continue to invest further in developing the Kenya market. The company has recently introduced its own office in Kenya. The products will be brought to Kenyan patients in partnership with Surgipharm.
Over the years, Cipla has been working with various partners in Kenya and has been supplying a basket of products across various key therapies - anti-HIV, anti-malarial, anti-asthma, gastroenterology, anti-infectives, cardiovascular and oncology among others.
Cipla is a global healthcare company which uses technology and innovation to meet the healthcare needs of patients in various therapy areas. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across almost 170 countries. Cipla’s turnover in 2013-14 was $1.7 billion.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1672.55 |
| Dr. Reddys Lab | 1235.85 |
| Cipla | 1236.15 |
| Zydus Lifesciences | 942.40 |
| Lupin | 2334.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: